MONDAY, June 6, 2022 (HealthDay News) Oral synthetic cannabinoid products with high tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratios are associated with moderate short-term improvement in chronic pain, according to a review
Researchers reviewing scientific literature found evidence of short-term benefits for treating chronic pain, but a notable lack of overall cannabis research.